TC
TVTX icon

TFS Capital’s Travere Therapeutics TVTX Stock Holding History

TFS Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-43,996
Closed -$601K – 1185
2016
Q1 		$601K Buy
43,996
+5,526
+14% +$83.8K 0.09% 393
2015
Q4 		$742K Sell
38,470
-55,760
-59% -$1.11M 0.08% 344
2015
Q3 		$1.91M Buy
+94,230
New +$2.79M 0.18% 179

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TFS Capital's TVTX Position: Q2 2016 in Review

TFS Capital sold out of Travere Therapeutics (TVTX) in Q2 2016, closing a stake of 43,996 shares — an estimated $601K sold.

TFS Capital first reported a position in TVTX in Q3 2015 and held it in 3 quarters. The position peaked at $1.91M in Q3 2015. 111 funds tracked by Wall St. Rank hold TVTX as of Q2 2016.

  • TFS Capital reported no remaining Travere Therapeutics position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 43,996 Travere Therapeutics shares in Q2 2016, an estimated $601K.
  • TFS Capital first reported a position in Travere Therapeutics in Q3 2015 and held it in 3 quarters.
  • TFS Capital's Travere Therapeutics position peaked at $1.91M in Q3 2015.
  • 111 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.